GE HealthCare Technologies IncNasdaq: GEHC
Health Care · Health Care Equipment
$61.68
+0.86%
Vol: 4.4M
Research Digest
Friday, June 19, 2026
GE HealthCare receives FDA clearance for AI radiation therapy planning software with built-in continuous update framework
GE HealthCare received FDA 510(k) clearance on June 4, 2026 for MIM Contour ProtégéAI+ 2.0, an AI-powered radiation therapy planning tool notable for its Predetermined Change Control Plan that allows continuous AI model updates across anatomical regions without requiring new clearances each time. The company also showcased cloud-enabled imaging solutions Genesis Radiology Workspace and InteleShare at the SIIM 2026 conference, and advanced its Portrait Mobile V2.0 hospital monitoring trial on June 10. Bank of America Securities assigned a Hold rating on June 12, 2026 as the stock traded around $61.50 on June 18, down approximately 22% year-to-date and near its 52-week low of $58.75. The FDA clearance with the continuous-update framework is strategically significant as it reduces regulatory friction for future AI improvements, though near-term financial impact remains modest.
Previous Market Intelligence
13 daysJun 18No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 17No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 16No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 15No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 14No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 21GE HealthCare unveiled AI-powered MR systems at ISMRM 2026 but stock pressured by guidance cut and lawsuitsNegative▶
GE HealthCare on May 11, 2026 announced advancements in MR technology at the ISMRM 2026 annual meeting, including the new SIGNA One AI workflow ecosystem, Sonic DL 2D deep-learning acceleration (FDA 510(k) pending), and SIGNA Studio software collaboration suite. Director Rodney Hochman purchased $100,364 of shares on May 13. However, the stock remains pressured following the Q1 earnings miss, cut full-year EPS guidance, and multiple securities law investigations. GEHC's 30-day return is down 18.62% and YTD return down 26.64%. Adjusted EBIT margin guidance was lowered by 40bps to 15.4%-15.7%. Risk: ongoing legal scrutiny, inflation pressures, and supply chain issues continue to weigh on the stock.
May 20GE HealthCare showcases AI-powered MR systems at ISMRM 2026 amid Q1 margin pressures and lowered guidanceMixed▶
GE HealthCare unveiled next-gen SIGNA MR technology and AI-powered MR systems at the ISMRM 2026 conference on May 11, including integration of icometrix brain MRI analysis and the FDA 510(k)-pending Sonic DL deep-learning acceleration. The product showcase comes amid a difficult stock period — shares are down 26.6% YTD after Q1 revenue of $5.1B with only 2.9% organic growth and management lowering full-year adjusted EBIT margin guidance to 15.4-15.7%. Goldman Sachs cited rising input costs, macro exposure, and tariffs as key concerns. Director Rodney Hochman bought 1,618 shares ($100,364) on May 13 in a vote of confidence. Shareholders backed the board, governance and compensation at the May 11 annual meeting.
May 19GE HealthCare director Rodney Hochman buys $100K in shares and unveils next-gen SIGNA MR technology amid post-earnings investigations.Mixed▶
On May 13, 2026, GE HealthCare director Rodney F. Hochman purchased 1,618 shares for approximately $100,364, signaling insider confidence after a sharp post-earnings drop. On May 11, 2026, the company unveiled next-generation SIGNA MR technologies at ISMRM 2026, including helium-free 1.5T MR and AI-powered Sonic DL for 2D imaging (510(k) pending), which could accelerate up to 85% of MR exams. At the May 7 annual meeting, shareholders elected eight directors, named Hochman independent lead director, and appointed Anne Madden as Nominating chair. However, the company missed Q1 adjusted earnings, cut full-year EPS guidance, and triggered multiple securities-law investigations, with the stock down 18.62% over 30 days and 26.64% YTD. Risk: legal investigations and continued guidance pressure overshadow product innovation.
May 18GE HealthCare unveiled AI-powered MR systems at ISMRM 2026 on May 11 and saw notable May 13 insider buy of 1,618 shares ($100,364) by Director Hochman.Mixed▶
On May 11, 2026, GE HealthCare announced next-gen SIGNA MR systems and AI-powered workflow technologies at the ISMRM 2026 Annual Meeting, including a 510(k)-pending Sonic DL 2D deep-learning acceleration that could benefit up to 85% of MR exams, plus two new MAGNUS head-only research scanner installations at King's College London and West China Hospital. The May 7 annual meeting elected eight directors, ratified Deloitte and named Rodney Hochman lead director. Director Hochman bought 1,618 shares ($100,364) on May 13 and Director Stromberg bought 1,000 shares ($61,689) on May 6. The stock has been under pressure since Q1's guidance cut, with adjusted EBIT margin guide lowered ~40bps to 15.4%-15.7% on inflation, tariffs, a PDx supplier recall and Patient Care Solutions weakness; Goldman Sachs lowered its outlook. Shares closed at $60.76 with a $60.67-$62.64 range on May 16.
May 15GE HealthCare Director Hochman buys $100K of stock May 13 amid ISMRM AI MR product showcaseMixed▶
On May 13, 2026, GE HealthCare Director Rodney F. Hochman disclosed an open-market purchase of 1,618 shares at $62.03 via a family trust, totaling about $100,364. Director William J. Stromberg bought 1,000 shares at $61.69 on May 6. At the May 7 annual meeting, shareholders elected eight directors, ratified Deloitte and approved executive compensation; Hochman was named independent lead director. At ISMRM 2026, GE HealthCare unveiled next-gen SIGNA MR, helium-free 1.5T MR, advanced 3T scanner and AI-powered workflow, and announced two new installations of its MAGNUS prototype head-only MR scanner at King's College London and West China Hospital. Shares trade around $61.30, down 24.5% YTD from $82.02 following an April Q1 guidance cut of $0.15 tied to a $250M tariff and supplier-quality inflation impact. Insider buying signals confidence but tariff/margin pressures persist.
May 14GE HealthCare unveils AI-powered MR systems at ISMRM 2026 with 510(k) pending Sonic DL technologyPositive▶
At ISMRM 2026 on May 11, GE HealthCare unveiled next-gen SIGNA MR technology including helium-free 1.5T MR and AI-powered workflow. Its Sonic DL deep-learning acceleration technique has 510(k) pending FDA status, designed to accelerate up to 85% of MR exams. Two new MAGNUS prototype installations announced at King's College London and West China Hospital. The company will spotlight AI-enabled radiation therapy solutions at ESTRO 2026 (May 12). Director William Stromberg bought 1,000 shares at $61.69 on May 6, signaling management confidence. Stock at $61.30, down ~25% YTD on healthcare-equipment headwinds. 14 analysts maintain Buy with $81.64 PT.
May 13GE HealthCare insiders bought heavily: Director Larry Culp purchased $5.0M in shares; stock down 23.4% YTD on guidance cut.Positive▶
GE HealthCare directors signaled strong confidence with significant insider buying: Director Lawrence Culp purchased 80,805 shares (~$5.0M) and Director William Stromberg bought 1,000 shares (~$61.7K) on May 6 at $61.69, with no offsetting sales. The stock is down 23.4% YTD trading near $63.29 amid lingering pressure from a prior guidance cut. Management presented at the BofA Health Care Conference on May 12. The annual meeting on May 7 saw eight directors re-elected. The company announced advancements in MR imaging at ISMRM 2026 including Sonic DL 2D imaging. Risk: China demand softness and tariff-related cost pressures on imaging equipment.
May 12GE HealthCare unveiled AI-powered MR systems at ISMRM 2026 May 10-11 including FDA 510(k)-pending Sonic DL deep-learning acceleration; Director Stromberg bought 1,000 shares May 6.Mixed▶
GE HealthCare announced advancements at the ISMRM 2026 Annual Meeting on May 10-11, including next-gen helium-free 1.5T MR, an advanced 3T scanner, and AI-powered workflow. The company announced FDA 510(k) pending status for Sonic DL for 2D imaging beyond cardiac cine, which could benefit up to 85% of MR exams. Two additional installations of the investigational MAGNUS head-only MR prototype were announced at King's College London and West China Hospital. Director Stromberg purchased 1,000 shares at $61.69 on May 6 ($61,689). Management presented at Bank of America's Health Care Conference on May 12. The stock is down roughly 25% YTD. Stock closed at $61.62 on May 11.
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| GEHCGE | $61.68 | +0.86% | +1.1% | 12.2x | 0.84 | $29.8B |
| ABTABBOTT | $88.64 | +0.16% | +5.4% | 15.8x | 0.61 | $166.2B |
| ISRGINTUITIVE | $406.90 | +1.17% | +6.0% | 36.1x | 1.46 | $150.9B |
| SYKSTRYKER | $309.23 | +2.68% | +4.1% | 19.5x | 0.78 | $125.2B |
| MDTMEDTRONIC | $79.43 | +1.64% | +3.8% | 13.0x | 0.58 | $106.5B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price below 200d MA — bearish structure.